Objective. To carry out a systematic analysis of the results of investigations of whether menopausal hormone therapy (MHT) can be used in patients who have been diagnosed with cervical cancer (CC) and/or completed treatment. Material and methods. The article includes the data of foreign articles published in Pubmed and Medline the past 20 years. Results. This paper presents the results of retrospective studies, the purpose of which was to determine the rate of recurrent CC in women receiving MHT compared with the control group. Conclusion. On the one hand, menopausal symptoms developing after surgery (after both panhysterectomy and organ-sparing surgery) and radiation with or without systemic (cytostatic) treatments continue to remain relevant to patients who have successfully completed treatment for squamous cell cancer of the cervix. On the other hand, clinicians need to have clinical protocols regulating the basic criteria for prescribing MHT.